# breast cancer - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 7
- Task type: PROGNOSIS
- Tissue / sample source: breast tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: 2eef237c25053f55d87c73e963368cae88b5c698447f11e7e98ebc594d62e5bb
- Response HTTP status: 200
- Prompt tokens: 30814
- Completion tokens: 12206
- Reasoning tokens: 0
- Total tokens: 43020
- API requests reported: 2
- Elapsed seconds: 79.241
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 685.605
- Question handoff seconds: 699.996
- Final benchmark system: E2seq; file rank 5/5; original repeat 7; model vendor: DeepSeek

---
# Multidimensional Interpretation of Prognostic Transcriptomic Results in Breast Cancer (OS Endpoint)

## 1. Overall Biological Interpretation

The dataset comprises 100 unique genes (106 input rows) with highly significant prognostic associations for overall survival in breast cancer: all 100 genes pass FDR ≤ 0.01, with 52 risk-associated genes (HR > 1) and 48 protective-associated genes (HR < 1). Effect sizes are modest but consistent (HR range approximately 0.79–1.26), suggesting that no single gene dominates prognosis but that coordinated biological programs collectively stratify survival.

The dominant biological theme is **proliferation and cell-cycle progression as adverse prognostic drivers**. A large cluster of risk-associated genes—including AURKA, TPX2, KIF20A, KIF4A, CDC20, UBE2C, UBE2S, CDCA5, NUSAP1, PRC1, CKAP2L, ZWINT, CENPO, PTTG1, TK1, FEN1, and CCNE2—are canonical components of mitotic progression, spindle assembly, DNA replication, and the APC/C ubiquitin ligase pathway. These genes form a coherent network (STRING edges linking AURKA–TPX2–KIF4A–NUSAP1–PRC1; CDC20–UBE2C–UBE2S; CDC20–PTTG1–ZWINT), and the retrieved GO/KEGG modules emphasize positive regulation of mitotic nuclear division and ubiquitin-protein ligase activity, with KEGG cell-cycle and oocyte-meiosis pathways represented.

The second major theme is **immune and stromal composition as protective**. Protective-associated genes include immune markers (FCER1A, CD1C, CD1E, KLRB1, JCHAIN, IL27RA, FLT3), stromal/extracellular-matrix genes (LAMA2, COL14A1, MFAP4, OGN, OMD, DST, ADAMTS8, RELN), and differentiation-associated transcription factors (TP63, STAT5A, STAT5B). The strong protective direction of these genes suggests that immune infiltration and differentiated stromal architecture are associated with better OS—a pattern consistent with published literature (e.g., PROS1 as a protective biomarker associated with immune infiltration in breast cancer, PMID 37827342).

A third, less dominant theme is **metabolic and stress-response remodeling**, with risk-associated genes including CPT1A (fatty acid oxidation), GPI (glycolysis), GSK3B (metabolic kinase), and LARP1/STIP1 (stress and translation regulation), alongside protective genes such as IGF1, IGFBP6, LEPR, and PDGFRA that reflect growth-factor signaling context.

**Critical caveat**: These are univariate survival associations from a single dataset. External statistical validation was not performed—no independent-cohort statistic is supplied. The pathway and network annotations are contextual evidence, not replication.

---

## 2. Core Biological Programs

### Program 1: Mitotic Spindle Assembly and Cell-Cycle Progression

- **Direction**: Risk-associated (HR > 1)
- **Major supporting genes**: AURKA, TPX2, KIF20A, KIF4A, NUSAP1, PRC1, CKAP2L, CDCA5, ZWINT, CENPO, TROAP, PTTG1, CCNE2
- **Pathway**: KEGG Cell cycle; Reactome "Cell Cycle, Mitotic"; GO: Positive Regulation of Mitotic Nuclear Division (GO:0045840)
- **Explanation**: These genes collectively encode proteins required for centrosome maturation, spindle bipolarity, kinetochore-microtubule attachment, and cytokinesis. AURKA and its cofactor TPX2 form a functional unit; KIF4A, KIF20A, and PRC1 participate in spindle midzone organization; NUSAP1 and CKAP2L contribute to spindle assembly. The coordinated risk direction across multiple independent components of this machinery indicates that high mitotic activity is an adverse prognostic feature.
- **Evidence strength**: Strong direct statistical support (many genes at FDR < 10⁻⁶); coherent network (STRING edges among AURKA, TPX2, KIF4A, NUSAP1, PRC1); GO/KEGG pathway recurrence. **Limitation**: These genes are proliferation markers; the association may reflect tumor grade or Ki67 index rather than a specific mitotic defect.

### Program 2: APC/C–Ubiquitin-Mediated Proteolysis and Cell-Cycle Exit Control

- **Direction**: Risk-associated (HR > 1)
- **Major supporting genes**: CDC20, UBE2C, UBE2S, PTTG1, ZWINT, CENPO, PSMD3
- **Pathway**: GO: Positive Regulation of Ubiquitin-Protein Ligase Activity (GO:1904668); Reactome "APC/C-mediated degradation of cell cycle proteins"
- **Explanation**: CDC20 activates the anaphase-promoting complex/cyclosome; UBE2C and UBE2S are its cognate E2 conjugating enzymes; PTTG1 (securin) is a canonical APC/C substrate whose degradation triggers sister-chromatid separation. ZWINT and CENPO participate in kinetochore signaling that gates APC/C activation. The co-occurrence of the activator, the E2 enzymes, and a key substrate in the same risk direction indicates a coordinated elevation of APC/C-dependent proteolysis—a hallmark of rapidly dividing cells.
- **Evidence strength**: Strong direct statistics; STRING network shows CDC20–UBE2C–UBE2S and CDC20–PTTG1–ZWINT edges; GO recurrence for ubiquitin ligase regulation. **Limitation**: Partially overlapping with Program 1 (cell cycle); the two programs are not fully independent.

### Program 3: Immune Cell Infiltration and Humoral Immunity

- **Direction**: Protective-associated (HR < 1)
- **Major supporting genes**: FCER1A, CD1C, CD1E, KLRB1, JCHAIN, IL27RA, FLT3, STAT5A, STAT5B
- **Pathway**: Reactome "Adaptive Immune System"; KEGG "Hematopoietic cell lineage"
- **Explanation**: FCER1A (Fcε receptor on dendritic cells), CD1C/CD1E (lipid antigen presentation), KLRB1 (NK/T-cell marker), and JCHAIN (immunoglobulin joining chain) collectively indicate the presence of dendritic cells, lymphocytes, and plasma cells within the tumor microenvironment. FLT3 is expressed on dendritic-cell progenitors; STAT5A/B mediate cytokine signaling in immune cells. The coordinated protective direction across these lineage markers suggests that immune infiltration—particularly antigen-presenting cell and lymphocyte content—is associated with better overall survival.
- **Evidence strength**: Strong direct statistics; literature support for immune infiltration–prognosis associations in breast cancer (e.g., PROS1–immune infiltration link, PMID 37827342). **Limitation**: This is likely a **tissue-composition signal**—tumor purity and immune-cell fraction may drive the association rather than tumor-cell-intrinsic biology. The genes may not be expressed by cancer cells themselves.

### Program 4: Extracellular Matrix Organization and Stromal Differentiation

- **Direction**: Protective-associated (HR < 1)
- **Major supporting genes**: LAMA2, COL14A1, MFAP4, OGN, OMD, DST, ADAMTS8, RELN, IGSF10, COL17A1
- **Pathway**: Reactome "Extracellular matrix organization"; GO: extracellular region (recurrent CC annotation)
- **Explanation**: These genes encode basement-membrane components (LAMA2, COL17A1), fibrillar collagen-associated proteins (COL14A1, MFAP4), proteoglycans (OGN, OMD), and matrix-modifying enzymes (ADAMTS8). Their protective direction suggests that a differentiated, organized stromal compartment—as opposed to a reactive desmoplastic stroma—is associated with favorable prognosis. TP63 and GRHL2 (risk-associated) may mark a more basal-like epithelial state, contrasting with the protective differentiated-stroma signature.
- **Evidence strength**: Moderate-to-strong direct statistics; extracellular-region GO recurrence. **Limitation**: Stromal gene expression in bulk tumor RNA reflects fibroblast/adipocyte content; the protective direction may be confounded by tumor subtype (e.g., luminal vs. basal) and by the inverse relationship between stromal content and tumor cellularity.

### Program 5: Growth-Factor Signaling and Metabolic Adaptation

- **Direction**: Mixed (both risk and protective genes)
- **Major supporting genes**: Risk: GSK3B, CPT1A, GPI, LARP1, STIP1, WNT7B; Protective: IGF1, IGFBP6, LEPR, PDGFRA, SPRY2
- **Pathway**: KEGG "Wnt signaling pathway" (GSK3B); Reactome "Metabolism"; KEGG "Glycolysis/Gluconeogenesis" (GPI)
- **Explanation**: This program captures metabolic and signaling context. Risk-associated genes include CPT1A (mitochondrial fatty-acid oxidation), GPI (glycolytic enzyme), and GSK3B (a kinase integrating Wnt, insulin, and cell-cycle signaling). Protective genes include IGF1 and IGFBP6 (IGF-axis components), LEPR (leptin receptor), and SPRY2 (negative regulator of RTK signaling). The opposing directions suggest that metabolic reprogramming toward glycolysis/fatty-acid oxidation is adverse, whereas intact growth-factor regulation and RTK negative feedback are favorable.
- **Evidence strength**: Moderate direct statistics; pathway annotations for GSK3B (KEGG cell cycle, Wnt). **Limitation**: This is the least coherent program—the genes span multiple pathways, and the "program" may represent several independent signals rather than one coordinated process. The protective IGF1/IGFBP6 direction is particularly context-dependent and may reflect stromal rather than tumor-cell expression.

---

## 3. Key Genes and Interaction Modules

### Module 1: AURKA–TPX2–KIF4A–NUSAP1–PRC1 (Spindle Module)

- **Statistics**: AURKA HR=1.189; TPX2 HR=1.202; KIF4A HR=1.199; NUSAP1 HR=1.194; PRC1 HR=1.186; all FDR < 1.3×10⁻⁶.
- **Role**: Core mitotic spindle assembly and cytokinesis.
- **Relationship type**: **Direct physical interaction** for AURKA–TPX2 (TPX2 is a well-established AURKA activator and spindle-targeting cofactor); **pathway co-membership** and **co-expression** for the broader module (STRING edges connect TPX2 to AURKA, KIF4A, NUSAP1, PRC1). These genes are co-regulated in the cell cycle and likely co-expressed in proliferating tumors, but direct physical interaction among all five is not established.
- **Why it matters**: This module is the strongest and most coherent risk-associated signal in the dataset.

### Module 2: CDC20–UBE2C–UBE2S–PTTG1 (APC/C Module)

- **Statistics**: CDC20 HR=1.191; UBE2C HR=1.210; UBE2S HR=1.184; PTTG1 HR=1.197; all FDR < 1.2×10⁻⁶.
- **Role**: APC/C activation and ubiquitin-dependent cell-cycle progression.
- **Relationship type**: **Direct physical interaction** is well documented for CDC20–APC/C and UBE2C/UBE2S as APC/C E2 enzymes; **pathway co-membership** for PTTG1 (securin, APC/C substrate). STRING edges confirm CDC20–UBE2C–UBE2S and CDC20–PTTG1 connections.
- **Why it matters**: This module bridges the mitotic program (Program 1) and the ubiquitin-proteolysis program (Program 2).

### Gene 3: GSK3B

- **Statistics**: HR=1.227; FDR=1.159×10⁻⁹ (risk-associated).
- **Role**: Serine/threonine kinase integrating Wnt/β-catenin signaling, cell-cycle control, and metabolism. STRING records show high-confidence interactions with CTNNB1, APC, AXIN1/2, and DVL1, placing it at the nexus of the destruction complex.
- **Relationship type**: **Direct physical interaction** with CTNNB1/APC/AXIN (STRING confidence ≥ 0.999); **regulatory interaction** in the Wnt pathway.
- **Why it matters**: GSK3B is a druggable kinase with pleiotropic roles; its risk direction in breast cancer OS is consistent with reports linking GSK3B activity to proliferation, though the direction is context-dependent (GSK3B can also act as a tumor suppressor in some settings).

### Gene 4: LARP1

- **Statistics**: HR=1.261; FDR=4.476×10⁻¹⁰ (risk-associated; strongest HR in the dataset).
- **Role**: RNA-binding protein regulating translation of TOP-motif mRNAs (including ribosomal proteins) in response to mTOR signaling.
- **Relationship type**: **Regulatory interaction** with mTOR pathway; **co-expression** with ribosomal biogenesis genes (UTP23 also risk-associated).
- **Why it matters**: LARP1 connects growth-factor signaling to translation and ribosome biogenesis; its strong risk association suggests that translationally driven growth is prognostically adverse.

### Gene 5: STIP1

- **Statistics**: HR=1.237; FDR=9.744×10⁻¹⁰ (risk-associated).
- **Role**: Hsp70/Hsp90 organizing protein (stress-response co-chaperone). Literature records link STIP1 to tumor immune infiltration and prognosis in pan-cancer analyses (PMID 37488801).
- **Relationship type**: **Direct physical interaction** with HSP70/HSP90 (well-established chaperone complex); **co-expression** with stress-response genes.
- **Why it matters**: STIP1 may reflect proteotoxic stress and chaperone dependence in aggressive tumors; it is a candidate therapeutic target given the clinical development of HSP90 inhibitors.

### Gene 6: PKMYT1

- **Statistics**: HR=1.244; FDR=9.744×10⁻¹⁰ (risk-associated).
- **Role**: Membrane-associated tyrosine/threonine kinase that inhibits CDK1 by phosphorylation (G2/M checkpoint).
- **Relationship type**: **Pathway co-membership** with the cell-cycle program; STRING connects PKMYT1 to PLK1 (regulatory interaction—PLK1 phosphorylates and inhibits PKMYT1 to promote mitotic entry).
- **Why it matters**: PKMYT1's risk direction is counterintuitive (it is a CDK1 inhibitor), suggesting that its elevated expression may reflect a G2/M checkpoint response in highly proliferative tumors rather than a driver. This illustrates the need for mechanistic validation.

### Gene 7: STAT5A/STAT5B

- **Statistics**: STAT5A HR=0.806; STAT5B HR=0.837; both FDR < 9×10⁻⁷ (protective-associated).
- **Role**: Signal transducers for prolactin, growth hormone, and cytokines; critical for mammary gland differentiation.
- **Relationship type**: **Direct physical interaction** between STAT5A and STAT5B (heterodimerization); **regulatory interaction** with JAK kinases. STRING shows STAT5A/B connected to STAT3, FLT3, and LEPR.
- **Why it matters**: The protective direction of STAT5A/B aligns with their role in maintaining luminal differentiation; loss of STAT5 signaling is associated with dedifferentiation and worse outcomes in breast cancer.

### Gene 8: TP63

- **Statistics**: HR=0.810; FDR=1.721×10⁻⁷ (protective-associated).
- **Role**: p53-family transcription factor marking basal/myoepithelial cells.
- **Relationship type**: **Regulatory interaction** with p53 family; **pathway co-membership** with differentiation programs.
- **Why it matters**: TP63's protective direction is notable because TP63 is a basal marker; its protective association may reflect myoepithelial content (a differentiated, non-invasive compartment) rather than tumor-cell expression—a composition caveat.

### Gene 9: CPT1A

- **Statistics**: HR=1.196; FDR=2.249×10⁻⁸ (risk-associated).
- **Role**: Rate-limiting enzyme for mitochondrial fatty-acid oxidation.
- **Relationship type**: **Pathway co-membership** with lipid metabolism; no direct interaction with the mitotic module.
- **Why it matters**: CPT1A risk direction supports a metabolic-reprogramming hypothesis (fatty-acid oxidation as an energy source for aggressive tumors), but this is a single-gene signal within the dataset and requires validation.

### Gene 10: PROS1

- **Statistics**: HR=0.836; FDR=1.078×10⁻⁶ (protective-associated).
- **Role**: Vitamin K-dependent anticoagulant protein with immune-modulatory functions.
- **Relationship type**: **Co-expression** with immune infiltration; literature records (PMID 37827342) describe PROS1 as a tumor suppressor associated with immune-cell infiltration in breast cancer.
- **Why it matters**: PROS1 exemplifies the protective immune/stromal signature; the literature provides external context, but the direction in this dataset is direct evidence only.

---

## 4. Validation Priorities

### Priority 1: Cell-Cycle/Mitotic Module as a Prognostic Biomarker Panel

- **Classification**: Biomarker
- **Why**: The AURKA–TPX2–CDC20–UBE2C module is the most statistically robust and biologically coherent risk signal (multiple genes, FDR < 10⁻⁶, network-supported).
- **Current dataset evidence**: Direct survival associations with consistent risk direction across >10 mitotic genes.
- **External evidence**: Mitotic gene signatures (e.g., CIN70, cell-cycle proliferation scores) are well-established prognostic markers across cancer types; literature supports AURKA, CDC20, and UBE2C as adverse prognostic markers in breast cancer.
- **Next step**: Test a mitotic-score composite in an independent breast cancer cohort with OS data; assess whether it adds prognostic value beyond grade, stage, and intrinsic subtype.
- **Conclusion status**: **Supported hypothesis** (direct dataset evidence + external literature, but no independent-cohort statistic in this analysis).

### Priority 2: Immune/Stromal Composition as the Driver of Protective Associations

- **Classification**: Confounding or composition check
- **Why**: The protective genes (FCER1A, CD1C, KLRB1, JCHAIN, LAMA2, COL14A1) likely reflect immune and stromal cell content rather than tumor-cell-intrinsic biology. Distinguishing these is essential before interpreting them as tumor biology.
- **Current dataset evidence**: Protective direction of immune and ECM genes; no cell-type deconvolution was performed.
- **External evidence**: Immune infiltration (particularly CD8+ T cells) is a favorable prognostic factor in breast cancer; stromal signatures are subtype-dependent.
- **Next step**: Perform cell-type deconvolution (CIBERSORTx, xCell) on the expression data; validate in single-cell or spatial transcriptomics to determine which cell types express the protective genes.
- **Conclusion status**: **Exploratory hypothesis**—the composition interpretation is plausible but unverified in this dataset.

### Priority 3: GSK3B as a Mechanistic and Therapeutic Candidate

- **Classification**: Mechanistic hypothesis / Therapeutic target
- **Why**: GSK3B is a druggable kinase with a strong risk association (HR=1.227, FDR=1.16×10⁻⁹) and well-characterized interactions with the Wnt destruction complex (STRING: CTNNB1, APC, AXIN1).
- **Current dataset evidence**: Risk direction in OS; pathway membership (KEGG cell cycle, Wnt).
- **External evidence**: GSK3B has context-dependent roles in cancer—both tumor-suppressive and oncogenic activities are reported. This ambiguity requires resolution.
- **Next step**: Determine whether GSK3B is expressed in tumor cells or stroma (IHC, single-cell); test GSK3B inhibition in patient-derived organoids or xenografts with high pathway activity; assess whether the risk association is subtype-specific.
- **Conclusion status**: **Exploratory hypothesis**—the direction is statistically robust but the mechanism and targetability are unproven.

### Priority 4: LARP1–STIP1 Stress/Translation Axis

- **Classification**: Mechanistic hypothesis
- **Why**: LARP1 (HR=1.261) and STIP1 (HR=1.237) are the two strongest risk-associated genes and connect translation control (mTOR–LARP1) and proteotoxic stress (HSP90–STIP1) to prognosis.
- **Current dataset evidence**: Strong risk direction for both genes; co-occurrence with UTP23 (ribosome biogenesis) in the same direction.
- **External evidence**: STIP1 is linked to immune infiltration in pan-cancer analyses (PMID 37488801); LARP1 is a known mTOR effector regulating ribosomal protein translation.
- **Next step**: Measure LARP1/STIP1 protein expression in breast cancer tissue; test whether genetic or pharmacological inhibition of LARP1 or STIP1 reduces proliferation in breast cancer cell lines; examine whether the risk association is independent of proliferation markers.
- **Conclusion status**: **Supported hypothesis** (strong direct statistics + mechanistic plausibility), but causal role unproven.

### Priority 5: CPT1A and Metabolic Reprogramming

- **Classification**: Mechanistic hypothesis
- **Why**: CPT1A is the sole clear metabolic gene with a strong risk association (HR=1.196, FDR=2.25×10⁻⁸) and represents a testable hypothesis linking fatty-acid oxidation to aggressive disease.
- **Current dataset evidence**: Risk direction in OS; no metabolomic data.
- **External evidence**: CPT1A is implicated in therapy resistance and metastasis in multiple cancer types; however, fatty-acid oxidation can also be protective in some contexts.
- **Next step**: Assess CPT1A expression by IHC in breast cancer cohorts; measure fatty-acid oxidation flux in CPT1A-high vs. CPT1A-low tumors (if fresh tissue available); test CPT1 inhibitors (e.g., etomoxir) in preclinical models.
- **Conclusion status**: **Exploratory hypothesis**—single-gene signal with plausible biology but no mechanistic validation in this dataset.

---

## 5. Evidence Grounding

| Interpretation | Direct Dataset Evidence | Pathway/Ontology | Protein Interaction/Regulatory | Disease-Association/Literature | Independence Assessment |
|---|---|---|---|---|---|
| Mitotic/cell-cycle risk program | Strong (multiple genes, FDR < 10⁻⁶) | GO: mitotic division; KEGG: cell cycle | STRING: AURKA–TPX2–KIF4A–NUSAP1–PRC1; CDC20–UBE2C–UBE2S | Extensive literature linking mitotic genes to poor breast cancer prognosis | Partially independent: pathway annotations and STRING derive from curated databases that may share underlying publications; direct statistics are independent of these annotations |
| APC/C ubiquitin-proteolysis risk | Strong (CDC20, UBE2C, UBE2S, PTTG1) | GO: ubiquitin ligase regulation | STRING: direct edges among module genes | Literature supports APC/C targets as prognostic markers | Pathway and network evidence overlap (both derive from cell-cycle biology); direct statistics are independent |
| Immune infiltration protective | Strong (FCER1A, CD1C, CD1E, KLRB1, JCHAIN) | Reactome: adaptive immunity | STRING: STAT3–STAT5A/B–FLT3–LEPR connections | Literature: immune infiltration favorable in breast cancer; PROS1–immune link (PMID 37827342) | Direct statistics and literature are independent; pathway annotations and literature may share sources |
| Stromal/ECM protective | Moderate (LAMA2, COL14A1, MFAP4, OGN) | GO: extracellular region | Limited interaction data | Stromal signatures are subtype-dependent in breast cancer | Direct statistics are primary; tissue-composition confounding is a major alternative explanation |
| Metabolic/translation risk (LARP1, STIP1, CPT1A, GSK3B) | Strong for individual genes | KEGG: cell cycle (GSK3B); Reactome: metabolism | GSK3B–CTNNB1/APC/AXIN direct interactions; STIP1–HSP90 | Literature: STIP1 pan-cancer immune link (PMID 37488801); GSK3B context-dependent roles | Direct statistics are robust; mechanistic interpretation is supported but not proven |

**Conflicts and caveats**:
- GSK3B has both tumor-suppressive and oncogenic reported roles; the risk direction here may be context-specific.
- TP63's protective direction conflicts with its role as a basal marker (basal tumors generally have worse prognosis). This may reflect myoepithelial content rather than tumor-cell TP63.
- STAT5A/B protective direction is consistent with luminal differentiation, but STAT5 signaling can also promote proliferation in some contexts.
- The immune-protective signal may be confounded by tumor purity and subtype (e.g., immune-rich triple-negative tumors have variable prognosis depending on the specific immune infiltrate).

---

## 6. Limitations and Alternative Explanations

### Limitation 1: Tissue and Cell-Composition Effects (Tumor Purity)

The protective genes (immune markers, ECM genes) and some risk genes (GRHL2, TP63) may reflect the relative abundance of immune cells, fibroblasts, myoepithelial cells, and cancer cells in the bulk tumor sample rather than tumor-cell-intrinsic biology. A tumor with high immune infiltration will show elevated FCER1A/CD1C/KLRB1 and better OS—but this does not mean the cancer cells themselves express these genes or that the genes drive the protective phenotype. **How to investigate**: Cell-type deconvolution, single-cell RNA-seq, spatial transcriptomics, or IHC to localize expression.

### Limitation 2: Disease Severity and Subtype Confounding

The mitotic risk program may be a proxy for tumor grade, proliferation index (Ki67), or intrinsic subtype (basal-like/HER2-enriched tumors are more proliferative and have worse outcomes). The protective immune/stromal program may be enriched in luminal A tumors. Without adjustment for stage, grade, and subtype, the gene–OS associations may reflect these clinical variables rather than independent gene effects. **How to investigate**: Multivariable Cox models including grade, stage, subtype; stratified analysis by intrinsic subtype.

### Limitation 3: Treatment Exposure

The OS endpoint reflects survival under whatever treatment patients received (surgery, chemotherapy, endocrine therapy, targeted therapy). Genes associated with chemoresistance (e.g., ABCB1, protective here) or sensitivity may show direction that reflects treatment response rather than intrinsic tumor aggressiveness. The protective direction of ABCB1 is notable because ABCB1 (P-glycoprotein) is usually associated with chemoresistance and worse outcomes—this may reflect a specific treatment context or a different biological role. **How to investigate**: Include treatment data in the model; stratify by treatment type; validate in treatment-naïve cohorts.

### Limitation 4: Association Versus Causation

All results are univariate survival associations. The mitotic genes are likely downstream consequences of proliferation rather than drivers; GSK3B, LARP1, and STIP1 may be passengers of a broader proliferative or stress program. The presence of a drug targeting a gene (e.g., GSK3B inhibitors) does not establish therapeutic relevance. **How to investigate**: Functional perturbation experiments (knockdown/overexpression), pathway inhibition studies, and causal inference frameworks (e.g., Mendelian randomization using eQTL data).

### Limitation 5: Batch, Platform, and Statistical Considerations

The dataset contains 6 duplicated gene/probe rows and 106 input rows for 100 genes; the analysis used deterministic display representatives. If the data come from multiple batches or platforms, batch effects could inflate or distort associations. All FDR values are ≤ 0.01, which is reassuring, but the HRs are modest (0.79–1.26), and the clinical utility of individual genes is limited. **How to investigate**: Examine batch structure, perform ComBat or similar correction, and test the prognostic value of gene combinations (scores) rather than individual genes.

---

## Summary Statement

The current dataset provides strong direct evidence that a coordinated mitotic/cell-cycle program (AURKA–TPX2–CDC20–UBE2C) is associated with worse overall survival in breast cancer, while immune and stromal composition markers (FCER1A, CD1C, JCHAIN, LAMA2, COL14A1) are associated with better survival; however, external statistical validation was not performed, the immune/stromal signals may reflect tissue composition rather than tumor-cell biology, and the mechanistic interpretations (GSK3B, LARP1/STIP1, CPT1A) remain exploratory hypotheses requiring functional validation and independent-cohort replication before any clinical or therapeutic conclusion can be drawn.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=17, external claims checked=0, external mismatches=0, status=passed.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 100/100 selected items (records returned); cbioportal 100/100 selected items (records returned); chembl 52/100 selected items (records returned); civic 12/100 selected items (records returned); clinicaltrials 57/100 selected items (records returned); clinvar 100/100 selected items (records returned); ensembl 100/100 selected items (records returned); europepmc 990 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 98/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 99/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 99/100 selected items (partially returned; some queries failed); mygene 100/100 selected items (records returned); omnipath 65/100 selected items (records returned); opentargets 100/100 selected items (records returned); pubmed 791 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 99/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 100/100 selected items (records returned)
Local databases: gutmgene 4/100 selected items (records returned); hmdb 31/100 selected items (records returned); string 100/100 selected items (records returned); trrust 40/100 selected items (records returned)
